Completed
TRUST-2TRUST-2: An Open-label Continuation Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)
What is being tested
Intravenous Treprostinil
Drug
Who is being recruted
Pulmonary Arterial Hypertension+1
+ Hypertension, Pulmonary
+ Lung Diseases
From 16 to 75 Years
+2 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 4
Interventional
Study Start: June 2005
Summary
Principal SponsorUnited Therapeutics
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: June 10, 2005
Actual date on which the first participant was enrolled.This was an open-label extension of Study RIV-PH-402, TRUST-1: Treprostinil for Untreated Symptomatic Pulmonary Arterial Hypertension (PAH) Trial. Subjects who completed Study RIV-PH-402 were eligible to enroll.
Official TitleTRUST-2: An Open-label Continuation Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)
Principal SponsorUnited Therapeutics
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
20 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 16 to 75 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Pulmonary Arterial HypertensionHypertension, PulmonaryLung DiseasesRespiratory Tract Diseases
Criteria
1 inclusion criteria required to participate
Subjects who were enrolled in and completed Study RIV-PH-402 (TRUST-1)
1 exclusion criteria prevent from participating
Subjects who were unblinded for potential rescue therapy in Study RIV-PH-402 and were found to be allocated to the Remodulin treatment group were not eligible to participate in this study.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalIntravenous treprostinil was supplied as 1 mg/mL.
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has no location dataSave this study to your profile to know when the location data is available.
CompletedNo study centers